BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meniconi RL, Komatsu S, Perdigao F, Boëlle PY, Soubrane O, Scatton O. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery. 2015;157:454-462. [PMID: 25633732 DOI: 10.1016/j.surg.2014.10.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Chua DW, Koh YX, Syn NL, Chuan TY, Yao TJ, Lee SY, Goh BKP, Cheow PC, Chung AY, Chan CY. Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis. Ann Surg Oncol 2021. [PMID: 33969464 DOI: 10.1245/s10434-021-09948-2] [Reference Citation Analysis]
2 Wan H, Lu S, Xu L, Yuan K, Xiao Y, Xie K, Wu H. Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:925362. [DOI: 10.3389/fonc.2022.925362] [Reference Citation Analysis]
3 Zhao Q, Xie L, Chen S, Xu X, Jiang T, Zheng S. Virtual navigation-guided radiofrequency ablation for recurrent hepatocellular carcinoma invisible on ultrasound after hepatic resection. Hepatobiliary & Pancreatic Diseases International 2020;19:532-40. [DOI: 10.1016/j.hbpd.2020.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kwon J, Chun KS, Song IS, Kim SH, Han S. Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment. Ann Hepatobiliary Pancreat Surg 2020;24:24-32. [PMID: 32181425 DOI: 10.14701/ahbps.2020.24.1.24] [Reference Citation Analysis]
5 Shindoh J, Kawamura Y, Kobayashi Y, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma. J Gastrointest Surg 2020;24:50-7. [PMID: 31190124 DOI: 10.1007/s11605-019-04277-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY, Cheng YF, Wang JH, Yen YH, Liu TT, Li WF, Chen CH. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg 2021:S0002-9610(21)00226-9. [PMID: 33840448 DOI: 10.1016/j.amjsurg.2021.03.065] [Reference Citation Analysis]
7 Ke R, Cai Q, Chen Y, Lv L, Jiang Y. Diagnosis and treatment of microvascular invasion in hepatocellular carcinoma. Eur Surg 2020;52:55-68. [DOI: 10.1007/s10353-019-0573-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Peng Z, Wu X, Li J, Pang H, Zhang Y, Lin M, Wang Z, Xiao H, Li B, Chen M, Feng S, Kuang M, Chen S. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. Int J Hyperthermia 2022;39:688-96. [PMID: 35469522 DOI: 10.1080/02656736.2022.2051613] [Reference Citation Analysis]
9 Fang T, Long G, Mi X, Su W, Mo L, Zhou L. Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy. Front Oncol 2022;12:876668. [PMID: 35686100 DOI: 10.3389/fonc.2022.876668] [Reference Citation Analysis]
10 Shindoh J, Kawamura Y, Kobayashi M, Akuta N, Okubo S, Matsumura M, Suzuki Y, Hashimoto M. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma. J Gastrointest Surg 2022. [PMID: 35715641 DOI: 10.1007/s11605-022-05388-9] [Reference Citation Analysis]
11 Cheng T, Cheng Y, Wu C, Tzeng I, Wang C. Predictors of recurrence in early hepatocellular carcinoma patients treated with surgical resection. Adv in Digestive Med. [DOI: 10.1002/aid2.13296] [Reference Citation Analysis]
12 Aierken Y, Kong LX, Li B, Liu XJ, Lu S, Yang JY. Liver fibrosis is a major risk factor for liver regeneration: A comparison between healthy and fibrotic liver. Medicine (Baltimore) 2020;99:e20003. [PMID: 32481371 DOI: 10.1097/MD.0000000000020003] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Iaria M, Bianchi G, Fazio F, Ardito F, Perri P, Pontarolo N, Conci S, Donadon M, Zanello M, Lai Q, Famularo S, Molfino S, Sciannamea I, Fumagalli L, Germani P, Floridi A, Ferrari C, Zimmitti G, Troci A, Zago M, Ferraro V, Cipriani F, Patauner S, La Barba G, Romano M, Zanus G, Ercolani G, Frena A, Aldrighetti L, Memeo R, Pinotti E, Crespi M, Hilal MA, Griseri G, Tarchi P, Chiarelli M, Antonucci A, Baiocchi GL, Romano F, Rossi M, Jovine E, Torzilli G, Ruzzenente A, Maestri M, Grazi GL, Giuliante F, Ferrero A, Dalla Valle R; HE.RC.O.LE.S. GROUP. The largest western experience on salvage hepatectomy for recurrent hepatocellular carcinoma: propensity score-matched analysis on behalf of He.RC.O.Le.Study Group. HPB (Oxford) 2022:S1365-182X(22)00001-6. [PMID: 35125292 DOI: 10.1016/j.hpb.2022.01.001] [Reference Citation Analysis]
14 Chen G, Wang R, Zhang C, Gui L, Xue Y, Ren X, Li Z, Wang S, Zhang Z, Zhao J, Zhang H, Yao C, Wang J, Liu J. Integration of pre-surgical blood test results predict microvascular invasion risk in hepatocellular carcinoma. Comput Struct Biotechnol J 2021;19:826-34. [PMID: 33598098 DOI: 10.1016/j.csbj.2021.01.014] [Reference Citation Analysis]
15 Wei M, Zhang Y, Chen M, Chen Y, Lau W, Peng Z. Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy. Front Oncol 2022;12:868429. [DOI: 10.3389/fonc.2022.868429] [Reference Citation Analysis]
16 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
17 Li J, Yang X, Huang L, Zhu X, Qiu M, Yan J, Yan Y, Wei S. Treatment Strategy for Post-hepatectomy Recurrent Hepatocellular Carcinoma Within the Milan Criteria: Repeat Resection, Local Ablative Therapy or Transarterial Chemoembolization? Indian J Surg. [DOI: 10.1007/s12262-022-03343-1] [Reference Citation Analysis]
18 Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, Kudo M, Kumada T, Roayaie S, Johnson PJ. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 2018;69:1284-93. [PMID: 30236834 DOI: 10.1016/j.jhep.2018.08.027] [Cited by in Crossref: 131] [Cited by in F6Publishing: 122] [Article Influence: 32.8] [Reference Citation Analysis]
19 Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
20 Li J, Huang L, Liu C, Qiu M, Yan J, Yan Y, Wei S. Risk factors and clinical outcomes of extrahepatic recurrence in patients with post-hepatectomy recurrent hepatocellular carcinoma. ANZ J Surg 2021;91:1174-9. [PMID: 33724680 DOI: 10.1111/ans.16737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tampaki M, Papatheodoridis GV, Cholongitas E. Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clin J Gastroenterol 2021;14:699-713. [PMID: 33774785 DOI: 10.1007/s12328-021-01394-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Liu J, Zhang W, Niu R, Li Y, Zhou X, Han X. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma. Saudi Med J 2020;41:376-82. [PMID: 32291424 DOI: 10.15537/smj.2020.4.24911] [Reference Citation Analysis]
23 Wakayama K, Kamiyama T, Yokoo H, Orimo T, Shimada S, Einama T, Kamachi H, Taketomi A. Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection. J Surg Oncol 2017;115:324-9. [PMID: 28192617 DOI: 10.1002/jso.24501] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
24 Kumar G, Goldberg SN, Wang Y, Velez E, Gourevitch S, Galun E, Ahmed M. Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition. Eur Radiol 2017;27:1238-47. [DOI: 10.1007/s00330-016-4405-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
25 Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study. J Vasc Interv Radiol 2016;27:1829-36. [PMID: 27553917 DOI: 10.1016/j.jvir.2016.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
26 Peng Z, Chen S, Xiao H, Wang Y, Li J, Mei J, Chen Z, Zhou Q, Feng S, Chen M, Qian G, Peng S, Kuang M. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.Radiology. 2019;292:237-247. [PMID: 31135299 DOI: 10.1148/radiol.2019181818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
27 Choi SB, Han HJ, Kim WB, Song TJ, Choi SY. VEGF Overexpression Predicts Poor Survival in Hepatocellular Carcinoma. Open Med (Wars). 2017;12:430-439. [PMID: 29318189 DOI: 10.1515/med-2017-0061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
28 Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J, Committee G. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 2016; 22(42): 9279-9287 [PMID: 27895416 DOI: 10.3748/wjg.v22.i42.9279] [Cited by in CrossRef: 129] [Cited by in F6Publishing: 138] [Article Influence: 21.5] [Reference Citation Analysis]
29 Wei F, Huang Q, Zhou Y, Luo L, Zeng Y. Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study. World J Surg Oncol 2021;19:175. [PMID: 34127007 DOI: 10.1186/s12957-021-02277-4] [Reference Citation Analysis]
30 Xu W, Liu F, Shen X, Li R. Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management. J Hepatocell Carcinoma 2020;7:233-56. [PMID: 33154956 DOI: 10.2147/JHC.S271498] [Reference Citation Analysis]
31 Sheng T, Wang B, Wang SY, Deng B, Qu L, Qi XS, Wang XL, Deng GL, Sun X. The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection. Medicine (Baltimore). 2015;94:e941. [PMID: 26091457 DOI: 10.1097/MD.0000000000000941] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
32 Schullian P, Laimer G, Putzer D, Levy E, Braunwarth E, Stättner S, Bale R. Stereotactic radiofrequency ablation as first-line treatment of recurrent HCC following hepatic resection. Eur J Surg Oncol 2020;46:1503-9. [PMID: 32222261 DOI: 10.1016/j.ejso.2020.03.207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
33 Ali MA, Li WF, Wang JH, Lin CC, Chen YJ, Lin TL, Lin TS, Lu SN, Wang CC, Chen CL. Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan. HPB (Oxford) 2016;18:851-60. [PMID: 27567971 DOI: 10.1016/j.hpb.2016.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 Kim JM, Joh JW, Yi NJ, Choi GS, Kwon CHD, Lee KW, Suh KS. Living donor liver transplantation should be cautiously considered as initial treatment in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection. Ann Transl Med 2020;8:288. [PMID: 32355732 DOI: 10.21037/atm.2020.02.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Li M, Wang Z, Cao J, Han B, Zou H, Zang Y, Wu L. Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections. European Journal of Surgical Oncology 2019;45:1684-90. [DOI: 10.1016/j.ejso.2019.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Joliat GR, Allemann P, Labgaa I, Demartines N, Halkic N. Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg. 2017;402:737-744. [PMID: 28497194 DOI: 10.1007/s00423-017-1582-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
37 Shen Y, Xiong W, Gu Q, Zhang Q, Yue J, Liu C, Wang D. Multi-Omics Integrative Analysis Uncovers Molecular Subtypes and mRNAs as Therapeutic Targets for Liver Cancer. Front Med (Lausanne) 2021;8:654635. [PMID: 34109194 DOI: 10.3389/fmed.2021.654635] [Reference Citation Analysis]
38 Liu Y, Sun L, Gao F, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Feng Y, Jiang Y, Wang X. A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e13536. [PMID: 30544459 DOI: 10.1097/MD.0000000000013536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
39 Jeong ES, Kim JM, Lim M, Yang J, Kwon JE, Choi GS, Joh JW. Laparoscopic versus open repeat liver resection for recurrent hepatocellular carcinoma in hepatectomy patients: inverse probability of treatment weighting. Updates Surg 2022. [PMID: 35218476 DOI: 10.1007/s13304-022-01257-x] [Reference Citation Analysis]
40 Zhang BH, Yang J, Jiang L, Lyu T, Kong LX, Tan YF, Li B, Zhu YF, Xi AY, Xu X, Yan LN, Yang JY. Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma. Genomics 2020;112:2763-71. [PMID: 32198063 DOI: 10.1016/j.ygeno.2020.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
41 Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carrafiello G, Azoulay D, Petrillo A, Curley SA. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. Oncologist 2019;24:e990-e1005. [PMID: 31217342 DOI: 10.1634/theoncologist.2018-0337] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 25.0] [Reference Citation Analysis]